KROS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Keros Therapeutics Inc (KROS) is not a strong buy at this time for a beginner investor with a long-term strategy. The company's weak financial performance, lack of positive news catalysts, and bearish technical indicators outweigh the potential for short-term gains. A hold position is recommended for now.
The technical indicators show a bearish trend with moving averages (SMA_200 > SMA_20 > SMA_5). The MACD is slightly positive at 0.19, but RSI at 40.431 is neutral, providing no clear signal. The stock is trading near its pivot level of 11.091, with key resistance at 11.482 and support at 10.699.
NULL identified. No recent news or significant events to act as a positive catalyst. Gross margin remains at 100%, which is a minor positive.
Weak financial performance in Q4 2025, with revenue down -87.34% YoY and net income dropping to -$23.46M (-49.03% YoY). Analysts have lowered the price target to $20, citing bearish sentiment in the near term. Lack of insider or hedge fund activity and no recent congress trading data further indicate limited confidence in the stock.
In Q4 2025, revenue dropped significantly (-87.34% YoY) to $385,000, and net income fell to -$23.46M (-49.03% YoY). EPS decreased to -0.87 (-23.68% YoY). Gross margin remained stable at 100%, but overall financial performance is weak.
Wells Fargo lowered the price target from $23 to $20 while maintaining an Overweight rating. Analysts expect bearish sentiment in the near term but are optimistic about potential longer-term catalysts from DMD data in 2027.
